Stephanie Davis
Stock Analyst at Barclays
(0.58)
# 4,138
Out of 5,113 analysts
94
Total ratings
31.82%
Success rate
-109.81%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $190 → $195 | $176.65 | +10.39% | 7 | Oct 22, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $32.67 | +37.76% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $13.09 | -61.79% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $43.74 | +71.47% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $6.86 | +2.04% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.77 | +116.61% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $3.94 | +382.23% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $340.47 | -14.82% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $198.38 | -32.96% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $46.42 | +24.95% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $3.54 | -15.25% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $252.50 | -1.39% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $16.43 | +76.51% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.16 | +374.86% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $26.34 | +29.08% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $217.55 | +7.10% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $2.37 | +617.30% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $95.68 | -20.57% | 5 | Jun 7, 2022 |
Quest Diagnostics
Oct 22, 2025
Maintains: Equal-Weight
Price Target: $190 → $195
Current: $176.65
Upside: +10.39%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $32.67
Upside: +37.76%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $13.09
Upside: -61.79%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $43.74
Upside: +71.47%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $6.86
Upside: +2.04%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.77
Upside: +116.61%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $3.94
Upside: +382.23%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $340.47
Upside: -14.82%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $198.38
Upside: -32.96%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $46.42
Upside: +24.95%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.54
Upside: -15.25%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $252.50
Upside: -1.39%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $16.43
Upside: +76.51%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.16
Upside: +374.86%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $26.34
Upside: +29.08%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $217.55
Upside: +7.10%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $2.37
Upside: +617.30%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $95.68
Upside: -20.57%